NCT04189419View on ClinicalTrials.gov

Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

January 14, 2022

Study Completion Date

March 15, 2022

Conditions
Pancreatitis, Acute
Interventions
BIOLOGICAL

SCM-AGH

SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).

OTHER

Placebo

Placebo will be administrated once a day for 3 days(D0, D1 and D2).

Trial Locations (7)

14584

Soonchunhyang University Hosptial Bucheon, Bucheon-si

22332

Inha University Hospital, Incheon

Unknown

Kyungpook National University Chilgok Hospital, Daegu

Dongguk University Ilsan Hospital, Goyang-si

Chonnam National University Medical School, Gwangju

Ajou University Hospital, Suwon

Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

SCM Lifescience Co., LTD.

INDUSTRY

NCT04189419 - Safety and Efficacy of SCM-AGH in Patients With Moderate to Severe Acute Pancreatitis | Biotech Hunter | Biotech Hunter